Evaluate.com β€” Website Analysis

Comprehensive traffic, valuation, and technical report for evaluate.com

$46,479
Estimated Worth
51
Daily Visitors
#150,607
Global Rank
$34
Daily Revenue
Last updated: Jan 10, 2024
πŸ“‹ About Evaluate.com

evaluate.com has a global rank of #150,607 with an estimated 51 daily visitors. Based on current traffic levels, the domain is valued at approximately $46,479.

The site runs on a .com (commercial) domain with servers located in United States, primary IP address 205.251.196.170, an active HTTPS configuration. Its homepage is titled β€œPharma commercial intelligence, news & analysis | Evaluate”.

πŸ”’ Is evaluate.com Safe?
SSL CertificateSecure
Security Score
0%
Strict-Transport-Securityβœ—
Content-Security-Policyβœ—
X-Content-Type-Optionsβœ—
X-Frame-Optionsβœ—
X-XSS-Protectionβœ—

Based on our analysis, evaluate.com implements HTTPS encryption and scores 0% on security headers. There is room for improvement in security configuration.

πŸ“Š Traffic & Revenue Estimates
Purchase/Sale Value$46,479
Daily Revenue$34
Monthly Revenue$968
Yearly Revenue$11,620
Daily Visitors51

All values are estimates based on publicly available traffic data.

πŸ“ˆ How Does evaluate.com Compare?
#150605 loopring.org
#150606 ccof.org
#150608 appycouple.com
#150609 seokicks.de

These are the websites closest to evaluate.com in global traffic ranking.

🌐 Website Overview
Websiteevaluate.com
Domain Age1995-12-21 05:00:00
TLD.com
Hosting LocationUnited States
Primary IP205.251.196.170
Visit Website Is it Down? Compare
πŸ”— DNS Records
HostTypeIPNameserver
evaluate.comA205.251.196.170ns-1194.awsdns-21.org.
evaluate.comA205.251.198.109ns-1645.awsdns-13.co.uk.
evaluate.comA205.251.192.31ns-31.awsdns-03.com.
evaluate.comA205.251.195.207ns-975.awsdns-57.net.
πŸ“‘ HTTP Response Headers
CF-Cache-Status
CF-RAY
Cache-Control
Connection
Content-Encoding
Content-Type
Content-language
Date
Expect-CT
Expires
Last-Modified
Permissions-Policy
Referrer-Policy
Server
Set-Cookie
Vary
X-Content-Type-Options
X-Drupal-Cache
X-Drupal-Dynamic-Cache
X-Frame-Options
X-Generator
X-UA-Compatible
X-XSS-Protection
πŸ“„ WHOIS Data
Domain NameEVALUATE.COM
RegistrarNetwork Solutions, LLC
Whois Serverwhois.networksolutions.com
Referral UrlNone
Updated Date2023-09-03 04:20:32, 2023-08-18 04:08:11
Creation Date1995-12-21 05:00:00
Expiration Date2030-12-20 05:00:00
Name ServersNS-1194.AWSDNS-21.ORG, NS-1645.AWSDNS-13.CO.UK, NS-31.AWSDNS-03.COM, NS-975.AWSDNS-57.NET
Statusok https://icann.org/epp#ok
Emails[email protected], [email protected]
Dnssecunsigned
NameStatutory Masking Enabled
OrgStatutory Masking Enabled
AddressStatutory Masking Enabled
CityStatutory Masking Enabled
StateNone
Registrant Postal CodeStatutory Masking Enabled
CountryUK
❓ Frequently Asked Questions About evaluate.com

How much is evaluate.com worth?

evaluate.com has an estimated value of $46,479 based on its traffic volume, global ranking, and projected advertising revenue.

How much traffic does evaluate.com get?

evaluate.com receives approximately 51 unique visitors per day. Its global traffic rank is #150,607.

Is evaluate.com safe to visit?

evaluate.com uses HTTPS encryption and has an active SSL certificate, which is a positive indicator of security. Always exercise caution when entering personal information on any website.

Where is evaluate.com hosted?

The servers for evaluate.com are located in United States.

Who owns evaluate.com?

Ownership details for evaluate.com can be found in the WHOIS section below. Many domain owners use privacy protection services to keep their registration details private.

How does evaluate.com rank compared to other .com websites?

With a global rank of #150,607, evaluate.com is a recognized .com domain.

πŸ”Ž Analyze Another Website
⚑ Quick Facts
Domainevaluate.com
TLD.com
SSLSecure
Server LocationUnited States
Global Rank#150,607
RegistrarNetwork Solutions, LLC
Domain Age1995-12-21 05:00:00
🏷️ Meta Info
TitlePharma commercial intelligence, news & analysis | Evaluate
DescriptionTrusted commercial intelligence, consensus forecasts, Vantage news and analysis for pharma, biotech and medtech industry - Explore Evaluate